Flying Publisher   

Home

Preface

Rationale

Awards

Rules and Conditions

Application

Books

Exclusive Sponsorship

Donations

 
We'll inform you

Privacy

About

FMI

About Roche

Roche is a leading pharmaceutical company in the treatment of Hepatitis C. With the launch of PEGASYS and COPEGUS in 2002, Roche entered the Hepatitis C market and rapidly assumed a leadership position in the marketplace.

Why is Roche sponsoring a Textbook on Viral Hepatitis?

Because:

• Hepatitis C is one of the most common chronic blood-borne infection
• Hepatitis C is a leading cause of cirrhosis, liver cancer and liver failure
• The field of treatment of viral hepatitis is evolving rapidly
• In many countries financial resources for books and education are limited
• Roche is in a leadership position regarding treatment of Hepatitis C and Hepatitis B

PEGASYS^® and COPEGUS^® Combination Therapy

PEGASYS and COPEGUS is the only pegylated interferon combination therapy to have demonstrated significantly superior benefits over conventional interferon combination therapy across all HCV genotypes irrespective of viral load.

In numerous clinical trials, PEGASYS and COPEGUS have consistently shown high overall sustained virological response rates (SVR; indicative of a cure for people with HCV), including in patients with difficult-to-treat disease such as genotype 1 HCV, cirrhosis, and HIV-HCV co-infection.

PEGASYS is approved for the treatment of both Hepatitis C and Hepatitis B.

References

Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55. Abstract: http://amedeo.com/lit.php?id=14996676

Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82. Abstract: http://amedeo.com/lit.php?id=12324553

Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32. Abstract: http://amedeo.com/lit.php?id=15578510

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50. Abstract: http://amedeo.com/lit.php?id=15282351

Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17. Abstract: http://amedeo.com/lit.php?id=15371578

Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95. Abstract: http://amedeo.com/lit.php?id=15987917